Expert Review of Anticancer Therapy最新文献_第3页

Targeting PGE2-IL-1β axis to impact future treatments for pancreatic ductal adenocarcinoma and its precursors. 靶向PGE2-IL-1β轴影响胰腺导管腺癌及其前体的未来治疗

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-08 DOI: 10.1080/14737140.2025.2450235

Paolo Riccardo Camisa, Nicoletta Caronni, Stefano Crippa

引用次数: 0

Efficacy and safety analysis of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the treatment of osteosarcoma: a systematic review and meta-analysis. 血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKIs）治疗骨肉瘤的疗效和安全性分析：系统综述和荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-01-01 Epub Date: 2024-11-26 DOI: 10.1080/14737140.2024.2433634

Boya Guan, Zhenhua Ge, Jinhong Zhang, Xin Feng

{"title":"Efficacy and safety analysis of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the treatment of osteosarcoma: a systematic review and meta-analysis.","authors":"Boya Guan, Zhenhua Ge, Jinhong Zhang, Xin Feng","doi":"10.1080/14737140.2024.2433634","DOIUrl":"10.1080/14737140.2024.2433634","url":null,"abstract":"Background: Osteosarcoma is a rare and aggressive bone cancer, with targeted therapy using VEGFR-TKIs (Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors) emerging as a promising treatment option.Research design and methods: This meta-analysis evaluated the efficacy and safety of VEGFR-TKIs in osteosarcoma treatment, analyzing studies from PubMed, Embase, Web of Science, and Cochrane databases until 18 September 2023, involving 14 trials with 447 patients.Results: Results indicated that monotherapy with VEGFR-TKIs had an objective response rate(ORR) of 16% (95% CI = 9-24%) and a disease control rate(DCR) of 65% (95% CI = 57-73%). The average progression-free survival(PFS) was 4.27 months(95% CI = 3.21-5.34), with overall survival(OS) at 9.26 months(95% CI = 7.75-10.77). Combined treatments led to an ORR of 7% (95% CI = 2-12%) and a DCR of 71% (95% CI = 54-88%), with PFS of 5.62 months(95% CI = 3.57-7.74) and OS of 11.84 months(95% CI = 9.26-14.43). Treatment-related adverse events occurred in 83% (95% CI = 74-92%), with severe events in 32% (95% CI = 3-61%).Conclusions: In conclusion, VEGFR-TKIs demonstrate effectiveness and tolerability in osteosarcoma treatment, providing significant disease control and survival advantages despite notable adverse event risks.Registration: PROSPERO (CRD42024579648).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"71-79"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer. Lurbinectedin是铂再挑战的有效替代品，可能恢复敏感复发小细胞肺癌患者的铂敏感性。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-01-01 Epub Date: 2024-12-12 DOI: 10.1080/14737140.2024.2438067

Manuel Dómine Gómez, Vivek Subbiah, Solange Peters, María Angeles Sala, José Trigo, Luis Paz-Ares, Antonio Nieto Archilla, Javier Gomez Garcia, Cristina Alvarez García, José Antonio López-Vilariño de Ramos, Carmen Kahatt Lopez, Cristian M Fernandez

{"title":"Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer.","authors":"Manuel Dómine Gómez, Vivek Subbiah, Solange Peters, María Angeles Sala, José Trigo, Luis Paz-Ares, Antonio Nieto Archilla, Javier Gomez Garcia, Cristina Alvarez García, José Antonio López-Vilariño de Ramos, Carmen Kahatt Lopez, Cristian M Fernandez","doi":"10.1080/14737140.2024.2438067","DOIUrl":"10.1080/14737140.2024.2438067","url":null,"abstract":"Introduction: Platinum rechallenge is recommended for patients with small cell lung cancer (SCLC) who relapse ≥90 days after completing first-line chemotherapy, although it may not always be the most suitable option.Areas covered: Articles for review were identified via PubMed and ClinicalTrials.gov searches, supplemented with non-indexed publications (e.g. conference abstracts) known to the manufacturer. We examined evidence for platinum re-exposure in patients with sensitive relapsed SCLC, and present lurbinectedin as a potential alternative. The complementary mechanisms of action of lurbinectedin and platinum, owing to opposite sensitivity of SCLC cells, may resensitize tumor cells to platinum. As efficacy outcomes with lurbinectedin are equivalent or better than those with platinum rechallenge and its hematological safety profile is more favorable, achieving maximum dose intensity is more likely. The simpler dosing schedule of lurbinectedin (1 vs 3 days) and lack of need for granulocyte colony-stimulating factor primary prophylaxis lessens treatment burden.Expert opinion: Incorporation of lurbinectedin into therapeutic algorithms for relapsed SCLC has challenged long-established treatment paradigms. Initial evidence indicates that using lurbinectedin after failure of first-line platinum may prolong the platinum-free interval and reserve platinum for later use. Current evidence supports lurbinectedin as a second-line option in patients with sensitive relapsed SCLC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"27-40"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venetoclax and beyond: New Horizons in CLL and AML therapy. Venetoclax及其他：CLL和AML治疗的新视野。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-04 DOI: 10.1080/14737140.2025.2449944

Matteo Molica, Salvatore Perrone

引用次数: 0

Statin use and ovarian cancer outcomes. 他汀类药物的使用与卵巢癌的结果。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-11-10 DOI: 10.1080/14737140.2024.2426551

John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein

{"title":"Statin use and ovarian cancer outcomes.","authors":"John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein","doi":"10.1080/14737140.2024.2426551","DOIUrl":"10.1080/14737140.2024.2426551","url":null,"abstract":"Introduction: Ovarian cancer contributed to 13,270 patient deaths in the United States during 2023 and is considered the most aggressive gynecologic malignancy. While surgery, chemotherapy and targeted medications have improved ovarian cancer patient outcomes, novel therapies that further bolster treatment efficacy without compromising toxicity represent an unmet clinical need.Areas covered: In the current review, we assessed the reported studies involving statin use and ovarian cancer outcomes; a preponderance of the evidence indicated that statins confer a survival benefit in ovarian cancer, especially for patients who underwent treatment post-diagnosis and for a prolonged interval.Expert opinion: The evidence involving a potential survival benefit from statin use in ovarian cancer remains controversial, especially with hydrophilic statins (e.g. pravastatin). While statin users may exhibit better ovarian cancer survival outcomes than non-statin users, additional research should evaluate the putative clinical benefits of statins in ovarian cancer via randomized controlled trials.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1199-1202"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The clinical potential of mechanistic models of individualized radiosensitivity. 个体化放射敏感性机制模型的临床潜力。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-23 DOI: 10.1080/14737140.2024.2444385

Shannon J Thompson, Stephen J McMahon

引用次数: 0

An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer. talazoparib联合enzalutamide治疗转移性去势抵抗性前列腺癌的评价。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-25 DOI: 10.1080/14737140.2024.2445152

Riccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, Nicole Brighi, Daniela Montanari, Cristian Lolli, Sara Bleve, Margherita Piras, Giuseppe Palmieri, Mario Scartozzi, Panagiotis Paliogiannis, Ugo De Giorgi

{"title":"An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.","authors":"Riccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, Nicole Brighi, Daniela Montanari, Cristian Lolli, Sara Bleve, Margherita Piras, Giuseppe Palmieri, Mario Scartozzi, Panagiotis Paliogiannis, Ugo De Giorgi","doi":"10.1080/14737140.2024.2445152","DOIUrl":"10.1080/14737140.2024.2445152","url":null,"abstract":"Introduction: Prostate cancer (PCa) is the second most common cancer diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment strategies have evolved, including the use of androgen receptor pathway inhibitors (ARPIs) and poly (ADP-ribose) polymerase inhibitors (PARPis).Areas covered: This review evaluates the clinical efficacy, safety, and future potential of combining talazoparib, a potent PARPi, with enzalutamide, a strong androgen receptor (AR) antagonist. The combination of these two drugs was evaluated by the TALAPRO-2 trial, demonstrating significant improvement in radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients, particularly those with Homologous Recombination Repair (HRR) gene mutations such as BRCA1/2.Expert opinion: Emerging biomarkers like TMPRSS2-ERG and RB1 gene mutations have been recently reported as potential predictors of clinical outcome in the TALAPRO-2 all-comers population. Genomic markers for homologous recombination deficiency (HRD) are other potential drivers of response to PARPi/ARPI combination. Further investigation is needed to refine treatment strategies, including targeting non-HRR mutations, and to expand the role of this combination therapy in earlier stages of prostate cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1221-1227"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database. 老年患者（≥65岁）III-IVB期不能手术的口腔鳞状细胞癌（OCSCC）的治疗模式和结果：来自SEER数据库的一项调查研究。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-20 DOI: 10.1080/14737140.2024.2441872

Wangyan Zhong, Hang Yuan, Ting Li, Jiwei Mao, Xueying Jin, Dongping Wu

{"title":"Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database.","authors":"Wangyan Zhong, Hang Yuan, Ting Li, Jiwei Mao, Xueying Jin, Dongping Wu","doi":"10.1080/14737140.2024.2441872","DOIUrl":"10.1080/14737140.2024.2441872","url":null,"abstract":"Background: The aim of this retrospective study is to explore therapeutic patterns and survival outcomes for a cohort of older patients with stage III-IVB inoperable oral squamous cell carcinoma (OCSCC) patients receiving radiation therapy (RT) with or without chemotherapy (CT).Methods: This study conducted a retrospective review of 316 patients ≥ 65 aged years with stage III-IVB OCSCC from the Surveillance, Epidemiology, and End Results (SEER) registry (2010-2015). It compared RT alone (n = 109) with RT+CT (n = 207), utilizing Kaplan-Meier and Log-rank tests.Results: The estimated overall survival (OS) and cancer-specific survival (CSS) rates at 3 years were 20.6% and 25.9%, respectively. Both univariate and multivariate analyses identified that age and treatment option as independent prognosticators of OS and CSS. Further subgroup analyses showed that the combination of RT and CT significantly improved OS for all OCSCC patients, except those with hard palate tumors. Moreover, this combined treatment approach was linked to enhanced CSS in patients with gingival and tongue squamous cell carcinoma.Conclusion: RT+CT significantly enhanced survival in elderly OCSCC patients, particularly those with gingival and tongue cancers, but not in those with hard palate tumors.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1311-1318"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking survival benefits: primary tumor resection in de novo stage IV breast cancer patients. 释放生存优势：对新发 IV 期乳腺癌患者进行原发肿瘤切除术。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-11-15 DOI: 10.1080/14737140.2024.2428695

Dong Chen, Yue Wang, Yuancan Pan, Boran Zhang, Wentao Yao, Yu Peng, Ganlin Zhang, Xiaomin Wang

{"title":"Unlocking survival benefits: primary tumor resection in de novo stage IV breast cancer patients.","authors":"Dong Chen, Yue Wang, Yuancan Pan, Boran Zhang, Wentao Yao, Yu Peng, Ganlin Zhang, Xiaomin Wang","doi":"10.1080/14737140.2024.2428695","DOIUrl":"10.1080/14737140.2024.2428695","url":null,"abstract":"Background: For patients with de novo stage IV breast cancer (BC), the conditions under which the primary tumor resection (PTR) may offer benefit remain unclear.Methods: The SEER database provides treatment data for patients with de novo stage IV BC. We screened cases of metastatic BC diagnosed from 2010 to 2015, with primary endpoints of overall survival (OS) and cancer-specific survival (CSS).Results: 9252 patients with stage IV de novo BC were enrolled. For OS, median survival time (MST) was 38 months with systematic treatment (ST) compared to 52 months with ST plus PTR (p < 0.001). For CSS, MST was 38 months for ST versus 54 months for ST plus PTR (p < 0.001). The results of the Cox proportional hazards regression analysis regarding PTR, for OS: bone metastasis (aHR 0.664, 95%CI 0.583-0.756, p < 0.001); liver-lung metastasis (aHR 0.528, 95%CI 0.327-0.853, p = 0.009). For CSS: bone metastasis (aHR 0.655, 95%CI 0.571-0.751, p < 0.001); liver-lung metastasis (aHR 0.549, 95%CI 0.336-0.889, p = 0.017). Kaplan-Meier analysis indicated that in patients with bone metastases and liver-lung metastases, PTR could improve survival outcomes.Conclusion: Liver-lung metastases and bone metastases in patients with de novo stage IV BC could enhance both OS and CSS through PTR.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1303-1310"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer. 术后血清CEA预测hr阳性/ her2阴性早期乳腺癌的预后。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-19 DOI: 10.1080/14737140.2024.2443009

Gozde Kavgaci, Taha Koray Sahin, Tugcenur Muderrisoglu, Serez Ileri, Deniz Can Guven, Sercan Aksoy

{"title":"Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer.","authors":"Gozde Kavgaci, Taha Koray Sahin, Tugcenur Muderrisoglu, Serez Ileri, Deniz Can Guven, Sercan Aksoy","doi":"10.1080/14737140.2024.2443009","DOIUrl":"10.1080/14737140.2024.2443009","url":null,"abstract":"Background: The prognostic role of preoperative carcinoembryonic antigen (CEA) in breast cancer is recognized, but the impact of postoperative CEA levels on survival in early breast cancer is uncertain.Research design and methods: We conducted a retrospective study of 921 non-metastatic breast cancer patients treated at anonymized. Patients were categorized as normal (CEA ≤3 µg/L) or elevated (CEA >3 µg/L).Results: Elevated postoperative CEA levels were associated with shorter disease-free survival (DFS) (median, 174.6 vs. 239.8 months; hazard ratio (HR): 1.80; 95% confidence interval (CI): 1.27-2.56; p < 0.001) and overall survival (OS) (median, 174.6 vs. 261.1 months; HR:2.34; 95% CI: 1.59-3.45; p < 0.001). Elevated CEA was associated with shorter DFS (median, 174.6 months vs. not reached (NR); HR:2.30; 95% CI: 1.03-5.19; p = 0.043) and OS (NR vs. NR; HR: 2.81; 95% CI: 1.06-7.48; p = 0.039) in stage 1, shorter DFS (median, 239. 8 vs. 141.1 months; HR: 1.95; 95% CI: 1.28-2.98; p = 0.002) and OS (median, 169 vs. 261.1 months; HR: 2.56; 95% CI: 1.6-4.12; p < 0.001) in stage 2 and shorter OS (median, 65 vs. 183.1 months; HR: 3.25; 95% CI: 1.19-8.83; p = 0.021) in stage 3.Conclusions: Elevated postoperative CEA indicates worse DFS and OS in patients with HR-positive/HER2-negative early breast cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1319-1326"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0